Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Endometrial Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 2Carcinosarcoma 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Endometrioid 1Breast Neoplasms 1

Interventions

Nivolumab 3Specimen Handling 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2sintilimab 1serabelisib 1sapanisertib 1rucaparib 1pembrolizumab 1palbociclib 1olaparib 1durvalumab 1ceralasertib 1adavosertib 1Therapeutics 1Restraint, Physical 1Radiation, Ionizing 1Radiation 1Platinum 1Paclitaxel 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Fulvestrant 1Congresses as Topic 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Endometrioid × ceralasertib × Gynecologic × Clear all
NCT04065269 2026-02-20

ATARI

Institute of Cancer Research, United Kingdom

Phase 2 Active not recruiting
174 enrolled
GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡